Multiple Sclerosis Target Patient Analysis
Multiple Sclerosis Target Patient Analysis provides a d breakdown of the unique aspects of multiple sclerosis patients taking one of the 12 branded products profiled. Although not every drug is ideal for each MS patient, there are similarities across MS drugs that share common patient characteristics. This strategy guide breaks down multiple sclerosis patient characteristics and discusses how well each brand aligns with them.
Determining the ideal treatment for a multiple sclerosis patient’s unique needs requires neurologists to evaluate several patient characteristics. The patient’s disease severity, age, lifestyle and other factors all play a role in which drug the doctor will prescribe.
As new MS drugs launch into the MS market, drug companies need to understand how neurologists weigh these factors when making treatment decisions. It’s also important for new product launch teams to understand their brands’ ideal patient characteristics.
The combination of patient characteristics makes up the ‘typical’ or target patient for each multiple sclerosis drug. Multiple Sclerosis Target Patient Analysis shows how the MS patient population is broken down based on their differing needs and which MS treatments best address those needs. With a thorough analysis patient attributes and how neurologists make treatment decisions, this guide provides key market insights to inform any multiple sclerosis brand’s launch strategy.
Overview of Multiple Sclerosis Target Patient Analysis
As neurologists evaluate their treatment options, they must factor in several key patient characteristics into their decisions. Multiple Sclerosis Target Patient Analysis breaks down those characteristics and shows how neurologists incorporate them at the brand level. The insights contained within this report depict the target multiple sclerosis patient for each branded drug profiled.
The data focus on how US neurologists approach each branded MS medications based on the following key patient’s traits:
- Disease severity
- Treatment history
- Lifestyle
- Age
- Comorbidities
Branded Treatments Analyzed
- Aubagio
- Gilenya
- Kesimpta
- Lemtrada
- Mavenclad
- Mayzent
- Ocrevus
- Ponvory
- Tysabri
- Tecfidera
- Vumerity
- Zeposia
Strategic Questions Answered within Multiple Sclerosis Target Patient Analysis
- Treatment Drivers: What are the key patient characteristics that drive HCP prescription decisions among MS treatments?
- Brand Ownership: What characteristics define the ‘typical’ patient receiving current MS treatments?
- Patient Trends: How do brands compare for patients who meet different clinical attribute criteria?
Summary of Strategic Insights found in Multiple Sclerosis Target Patient Analysis
- While Ocrevus leads in patient share, it is not dominating, and MS brands seem to be relatively evenly distributed in patient share. Indeed, Kesimpta seems to be the one most rapidly gaining share.
- Gilenya is a good intermediate option that provides a balance of efficacy, safety, and convenience for those patients who are mild to moderate and have failed 1 DMT. Zeposia is also competing for this patient.
- Older standard of care like Lemtrada, Gilenya, Tecfidera, and Tysabri are the most rapidly decreasing in prescription volume, while new therapies like Kesimpta, Ponvory, and Ocrevus are quickly taking their place.
Benefits of Purchasing Multiple Sclerosis Target Patient Analysis
- Cost-efficient analysis about MS patient trends to support your strategic marketing decisions.
- Insights drawn from in-depth interviews among US KOLs and surveys of more than 125 neurologists
- A complimentary 30-minute workshop with you (and your team)
- Unlimited support from Vivisum’s multiple sclerosis strategist for 1-year.
Table of Contents
Executive Summary – 6
Research Methodology: Robust Insights from US Neurologists – 7
The Strategic Six: Key Insights About
Target Patients for MS Brands – 8
‘Typical’ Patient Map – 9
MS Patient Archetypes – 10
MS Brand Target Patient Profiles – 11
Patient Share by Multiple Sclerosis Treatment – 12
12-month Prescribing Trends – 13
Ocrevus Patient Profile – 14
- Ocrevus ‘Typical’ Patient Summary – 15
- Ocrevus Patient ‘Typical’ Disease Severity – 16
- Ocrevus Patient ‘Typical’ Treatment History – 17
- Ocrevus Patient: ‘Typical’ Lifestyle – 18
- Ocrevus Patient: ‘Typical’ Age – 19
- Ocrevus Patient: ‘Typical’ Comorbidities – 20
Tecfidera Patient Profile – 21
- Tecfidera ‘Typical’ Patient Summary – 22
- Tecfidera Patient ‘Typical’ Disease Severity – 23
- Tecfidera Patient ‘Typical’ Treatment History – 24
- Tecfidera Patient: ‘Typical’ Lifestyle – 25
- Tecfidera Patient: ‘Typical’ Age – 26
- Tecfidera Patient: ‘Typical’ Comorbidities – 27
Tysabri Patient Profile – 28
- Tysabri ‘Typical’ Patient Summary – 29
- Tysabri Patient ‘Typical’ Disease Severity – 30
- Tysabri Patient ‘Typical’ Treatment History – 31
- Tysabri Patient: ‘Typical’ Lifestyle – 32
- Tysabri Patient: ‘Typical’ Age – 33
- Tysabri Patient: ‘Typical’ Comorbidities – 34
Gilenya Patient Profile – 35
- Gilenya ‘Typical’ Patient Summary – 36
- Gilenya Patient ‘Typical’ Disease Severity – 37
- Gilenya Patient ‘Typical’ Treatment History – 38
- Gilenya Patient: ‘Typical’ Lifestyle – 39
- Gilenya Patient: ‘Typical’ Age – 40
- Gilenya Patient: ‘Typical’ Comorbidities – 41
Aubagio Patient Profile – 42
- Aubagio ‘Typical’ Patient Summary – 43
- Aubagio Patient ‘Typical’ Disease Severity – 44
- Aubagio Patient ‘Typical’ Treatment History – 45
- Aubagio Patient: ‘Typical’ Lifestyle – 46
- Aubagio Patient: ‘Typical’ Age – 47
- Aubagio Patient: ‘Typical’ Comorbidities – 48
Lemtrada Patient Profile – 49
- Lemtrada ‘Typical’ Patient Summary – 50
- Lemtrada Patient ‘Typical’ Disease Severity – 51
- Lemtrada Patient ‘Typical’ Treatment History – 52
- Lemtrada Patient: ‘Typical’ Lifestyle – 53
- Lemtrada Patient: ‘Typical’ Age – 54
- Lemtrada Patient: ‘Typical’ Comorbidities – 55
Kesimpta Patient Profile – 56
- Kesimpta ‘Typical’ Patient Summary – 57
- Kesimpta Patient ‘Typical’ Disease Severity – 58
- Kesimpta Patient ‘Typical’ Treatment History – 59
- Kesimpta Patient: ‘Typical’ Lifestyle – 60
- Kesimpta Patient: ‘Typical’ Age – 61
- Kesimpta Patient: ‘Typical’ Comorbidities – 62
Zeposia Patient Profile – 63
- Zeposia ‘Typical’ Patient Summary – 64
- Zeposia Patient ‘Typical’ Disease Severity – 65
- Zeposia Patient ‘Typical’ Treatment History – 66
- Zeposia Patient: ‘Typical’ Lifestyle – 67
- Zeposia Patient: ‘Typical’ Age – 68
- Zeposia Patient: ‘Typical’ Comorbidities – 69
Mayzent Patient Profile – 70
- Mayzent ‘Typical’ Patient Summary – 71
- Mayzent Patient ‘Typical’ Disease Severity – 72
- Mayzent Patient ‘Typical’ Treatment History – 73
- Mayzent Patient: ‘Typical’ Lifestyle – 74
- Mayzent Patient: ‘Typical’ Age – 75
- Mayzent Patient: ‘Typical’ Comorbidities – 76
Vumerity Patient Profile – 77
- Vumerity ‘Typical’ Patient Summary – 78
- Vumerity Patient ‘Typical’ Disease Severity – 79
- Vumerity Patient ‘Typical’ Treatment History – 80
- Vumerity Patient: ‘Typical’ Lifestyle – 81
- Vumerity Patient: ‘Typical’ Age – 82
- Vumerity Patient: ‘Typical’ Comorbidities – 83
Ponvory Patient Profile – 84
- Ponvory ‘Typical’ Patient Summary – 85
- Ponvory Patient ‘Typical’ Disease Severity – 86
- Ponvory Patient ‘Typical’ Treatment History – 87
- Ponvory Patient: ‘Typical’ Lifestyle – 88
- Ponvory Patient: ‘Typical’ Age – 89
- Ponvory Patient: ‘Typical’ Comorbidities – 90
Mavenclad Patient Profile – 91
- Mavenclad ‘Typical’ Patient Summary – 92
- Mavenclad Patient ‘Typical’ Disease Severity – 93
- Mavenclad Patient ‘Typical’ Treatment History – 94
- Mavenclad Patient: ‘Typical’ Lifestyle – 95
- Mavenclad Patient: ‘Typical’ Age – 96
- Mavenclad Patient: ‘Typical’ Comorbidities – 97
MS Prescription Trends in Patient Sub-groups – 98
MS Prescription Trends by Disease Severity – 99
- Disease Severity: Low Activity Trends – 100
- Disease Severity: Mild to Moderate Patient Trends – 101
- Disease Severity: Moderate to Severe Patient Trends – 102
- Disease Severity: High Activity Patient Trends – 103
MS Prescription Trends by Treatment History – 104
- Treatment History: Treatment Naïve – 105
- Treatment History: Previously Failed 1 DMT – 106
- Treatment History: Previously Failed 2 DMTs – 107
- Treatment History: Previously Failed 3 DMTs – 108
- Treatment History: Previously Failed 4+ DMTs – 109
MS Prescription Trends by Lifestyle – 110
- Lifestyle: Very Active and Busy – 111
- Lifestyle: Moderately Active – 112
- Lifestyle: Less Active or Sedentary – 113
MS Prescription Trends by Patient Age – 114
- Patient Age: 24 or Younger – 115
- Patient Age: 25-34 – 116
- Patient Age: 25-44 – 117
- Patient Age: 45-54 – 118
- Patient Age: 55 or older – 119
MS Prescription Trends by Comorbidities – 120
- Comorbidities: Good Health with Few or No Comorbidities – 121
- Comorbidities: Moderate Health with Some Comorbidities – 122
- Comorbidities: Poor Health with Multiple Comorbidities – 123
Contact – 124
